FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

9 letters match. Newest first.

  1. Platinum Biologics LLC

    FDA says Platinum Biologics sells unapproved umbilical cord and exosome biologics without required licenses or approvals.

    High risk
  2. Innate Healthcare Institute

    FDA warned Arizona clinic Innate Healthcare Institute for selling unapproved umbilical cord stem cells marketed to treat autism.

    High risk
  3. BioStem Life Sciences

    FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.

    High risk
  4. Chara Biologics, Inc.

    FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.

    High risk
  5. Evolutionary Biologics Inc.

    FDA warned Evolutionary Biologics that its exosome and umbilical-cord products are unapproved new drugs and unlicensed biologics sold with disease-treatment claims.

    High risk
  6. Mother Stem Institute, Corp.

    FDA warns Mother Stem Institute over unapproved fat-derived SVF 'stem cell' biologic marketed for serious diseases.

    High risk
  7. Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.

    FDA says Berkeley Biologics' viable bone matrix products are unapproved drugs, with donor screening failures tied to tuberculosis infections.

    High risk
  8. MiMedx Group, Inc.

    FDA cites MiMedx for marketing placental product AXIOFILL without BLA or IND and for CGMP failures.

    High risk
  9. Signature Biologics, LLC

    FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.

    High risk